Eligible participants were randomly assigned ( 1:1 ) via computer-generated permuted block randomisation to rifampicin 300 mg twice daily or matching placebo ( 50 mg riboflavin capsules ) , stratified by subtype ( parkinsonian vs cerebellar ) , with a block size of four .